A Phase II Study of Nivolumab: A Multicenter, Open-Label, Single Arm Study in Malignant Pleural Mesothelioma (MERIT)

被引：10

作者：

Goto, Y. ^{[1
]}

Okada, M. ^{[2
]}

Kijima, T. ^{[3
]}

Aoe, K. ^{[4
]}

Kato, T. ^{[5
]}

Fujimoto, N. ^{[6
]}

Nakagawa, K. ^{[7
]}

Takeda, Y. ^{[8
]}

Hida, T. ^{[9
]}

Kanai, K. ^{[10
]}

Imamura, F. ^{[11
]}

Oizumi, S. ^{[12
]}

Takahashi, T. ^{[13
]}

Takenoyama, M. ^{[14
]}

Tanaka, H. ^{[15
]}

Ohe, Y. ^{[16
]}

机构：

[1] Natl Canc Ctr, Tokyo, Japan

[2] Hiroshima Univ, Hiroshima, Japan

[3] Hyogo Coll Med, Nishinomiya, Hyogo, Japan

[4] Natl Hosp Org Yamaguchi Ube Med Ctr, Ube, Yamaguchi, Japan

[5] Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Kanagawa, Japan

[6] Okayama Rosai Hosp, Asbestos Study Ctr, Okayama, Japan

[7] Kinki Univ, Fac Med, Med Oncol, Osaka, Japan

[8] Natl Ctr Global Hlth & Med, Resp Med, Tokyo, Japan

[9] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan

[10] Wakayama Med Univ, Wakayama, Japan

[11] Osaka Int Canc Inst, Dept Gen Thorac Surg, Osaka, Japan

[12] Natl Hosp Org Hokkaido Canc Ctr, Dept Resp Med, Sapppro, Japan

[13] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan

[14] Kyushu Natl Canc Ctr, Dept Thorac Oncol, Fukuoka, Fukuoka, Japan

[15] Niigata Canc Ctr Hosp, Internal Med, Niigata, Japan

[16] Natl Canc Ctr, Thorac Oncol, Tokyo, Japan

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期

关键词：

malignant pleural mesothelioma; Nivolumab; PD-1;

D O I：

10.1016/j.jtho.2017.09.634

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA 19.01

引用

页码：S1883 / S1883

页数：1

共 50 条

[31] Multicenter, nonrandomized, open-label Phase 1b study of FP-1039/GSK3052230 with chemotherapy: results in malignant pleural mesothelioma (MPM)
Trigo Perez, J. M.
van Brummelen, E.
Levchenko, E.
Gomez, M. Domine
Fennell, D. A.
Kindler, H. L.
Viteri, S.
Gadgeel, S.
Lopez, P. Garrido
Kostorov, V.
Morgensztern, D.
Orlov, S.
Paik, P. K.
Vansteenkiste, J. F.
Wang, X.
Sharabidze, A.
Deyoung, M. P.
Baker, K. P.
Yan, L.
Mitrica, I.
ANNALS OF ONCOLOGY, 2017, 28
[32] Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study
Jung, Ki Sun
Lee, Su Jin
Park, Se Hoon
Lee, Jae-Lyun
Lee, Se-Hoon
Lim, Jae Yun
Kang, Jung Hun
Lee, Suee
Rha, Sun Young
Lee, Kyung Hee
Kim, Ho Young
Lim, Ho Yeong
CANCER RESEARCH AND TREATMENT, 2018, 50 (02): : 488 - 494
[33] SINGLE ARM, OPEN-LABEL, MULTICENTER PHASE II STUDY OF THE RADIONUCLIDE 177LU-DOTATATE (LUTATHERA) IN ADULTS WITH ADVANCED INTRACRANIAL MENINGIOMA
Kurz, Sylvia
Zan, Elcin
Gurewitz, Jasone
Cordova, Christine
Troxel, Andrea B.
Sawaged, Zacharia
Sevillano-Torres, Hector
Silverman, Joshua S.
Snuderl, Matija
Zagzag, David
Golfinos, John
Kondziolka, Douglas
Sulman, Erik
NEURO-ONCOLOGY, 2020, 22 : 54 - 55
[34] Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma
Zimmer, Lisa
Eigentler, Thomas K.
Kiecker, Felix
Simon, Jan
Utikal, Jochen
Mohr, Peter
Berking, Carola
Kaempgen, Eckhart
Dippel, Edgar
Stadler, Rudolf
Hauschild, Axel
Fluck, Michael
Terheyden, Patrick
Rompel, Rainer
Loquai, Carmen
Assi, Zeinab
Garbe, Claus
Schadendorf, Dirk
JOURNAL OF TRANSLATIONAL MEDICINE, 2015, 13
[35] NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
Haakensen, Vilde Drageset
Nowak, Anna K.
Ellingsen, Espen Basmo
Farooqi, Saima Jamil
Bjaanaes, Maria Moksnes
Horndalsveen, Henrik
Mcculloch, Tine
Grundberg, Oscar
Cedres, Susana M.
Helland, Aslaug
JOURNAL OF TRANSLATIONAL MEDICINE, 2021, 19 (01)
[36] NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
Vilde Drageset Haakensen
Anna K. Nowak
Espen Basmo Ellingsen
Saima Jamil Farooqi
Maria Moksnes Bjaanæs
Henrik Horndalsveen
Tine Mcculloch
Oscar Grundberg
Susana M. Cedres
Åslaug Helland
Journal of Translational Medicine, 19
[37] Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma
Lisa Zimmer
Thomas K. Eigentler
Felix Kiecker
Jan Simon
Jochen Utikal
Peter Mohr
Carola Berking
Eckhart Kämpgen
Edgar Dippel
Rudolf Stadler
Axel Hauschild
Michael Fluck
Patrick Terheyden
Rainer Rompel
Carmen Loquai
Zeinab Assi
Claus Garbe
Dirk Schadendorf
Journal of Translational Medicine, 13
[38] Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: A multicenter, open-label, single-arm phase II study
Srimuninnimit, Vichien
Sriuranpong, Virote
Suwanvecho, Suthida
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 (03) : 255 - 260
[39] Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study
Deng, Li-Juan
Zhou, Ke-Shu
Liu, Li-Hong
Zhang, Ming-Zhi
Li, Zhi-Ming
Ji, Chun-Yan
Xu, Wei
Liu, Ting
Xu, Bing
Wang, Xin
Gao, Su-Jun
Zhang, Hui-Lai
Hu, Yu
Li, Yan
Cheng, Ying
Yang, Hai-Yan
Cao, Jun-Ning
Zhu, Zun-Min
Hu, Jian-Da
Zhang, Wei
Jing, Hong-Mei
Ding, Kai-Yang
Zhang, Xiang-Yang
Zhao, Ren -Bin
Zhang, Bin
Tian, Ya -Min
Song, Yong-Ping
Song, Yu-Qin
Zhu, Jun
BLOOD ADVANCES, 2023, 7 (16) : 4349 - 4357
[40] Everolimus for Relapsed/Refractory Classical Hodgkin Lymphoma: Multicenter, Open-Label, Single-Arm, Phase 2 Study
Johnston, Patrick B.
Pinter-Brown, Lauren
Rogerio, Jaqueline
Warsi, Ghulam
Chau, Quincy
Ramchandren, Radhakrishnan
BLOOD, 2012, 120 (21)

← 1 2 3 4 5 →